Which has higher valuation and earnings, LH or HSIC?

Labcorp has higher revenue and earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Labcorp $14.14B 1.54 $876.50M $11.29 23.54 Henry Schein $13.38B 0.66 $398M $3.31 23.40

Is LH or HSIC more profitable?

Labcorp has a net margin of 6.66% compared to Henry Schein's net margin of 2.95%. Labcorp's return on equity of 16.29% beat Henry Schein's return on equity. Company Net Margins Return on Equity Return on Assets Labcorp 6.66% 16.29% 7.62% Henry Schein 2.95% 15.44% 5.53%

Does the media favor LH or HSIC?

In the previous week, Henry Schein had 1 more articles in the media than Labcorp. MarketBeat recorded 10 mentions for Henry Schein and 9 mentions for Labcorp. Henry Schein's average media sentiment score of 1.61 beat Labcorp's score of 1.29 indicating that Henry Schein is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Henry Schein 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, LH or MEDP?

Labcorp has higher revenue and earnings than Medpace. Labcorp is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Labcorp $14.14B 1.54 $876.50M $11.29 23.54 Medpace $2.68B 4.84 $451.12M $15.91 28.55

Is LH or MEDP more profitable?

Medpace has a net margin of 17.19% compared to Labcorp's net margin of 6.66%. Medpace's return on equity of 120.89% beat Labcorp's return on equity. Company Net Margins Return on Equity Return on Assets Labcorp 6.66% 16.29% 7.62% Medpace 17.19% 120.89% 24.79%

Does the media prefer LH or MEDP?

In the previous week, Medpace had 36 more articles in the media than Labcorp. MarketBeat recorded 45 mentions for Medpace and 9 mentions for Labcorp. Labcorp's average media sentiment score of 1.29 beat Medpace's score of 0.27 indicating that Labcorp is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 13 Very Positive mention(s) 0 Positive mention(s) 30 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMN or LH?

In the previous week, AMN Healthcare Services had 2 more articles in the media than Labcorp. MarketBeat recorded 11 mentions for AMN Healthcare Services and 9 mentions for Labcorp. Labcorp's average media sentiment score of 1.29 beat AMN Healthcare Services' score of 0.31 indicating that Labcorp is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Labcorp 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, BIO or LH?

Labcorp has higher revenue and earnings than Bio-Rad Laboratories. Labcorp is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Rad Laboratories $2.58B 3.05 $759.90M $6.07 48.44 Labcorp $14.14B 1.54 $876.50M $11.29 23.54

Does the media favor BIO or LH?

In the previous week, Labcorp had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 9 mentions for Labcorp and 3 mentions for Bio-Rad Laboratories. Labcorp's average media sentiment score of 1.29 beat Bio-Rad Laboratories' score of 0.43 indicating that Labcorp is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Labcorp 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, CAH or LH?

Cardinal Health has higher revenue and earnings than Labcorp. Labcorp is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardinal Health $222.58B 0.22 $1.56B $6.54 31.47 Labcorp $14.14B 1.54 $876.50M $11.29 23.54

Does the media prefer CAH or LH?

In the previous week, Labcorp had 5 more articles in the media than Cardinal Health. MarketBeat recorded 9 mentions for Labcorp and 4 mentions for Cardinal Health. Labcorp's average media sentiment score of 1.29 beat Cardinal Health's score of 0.80 indicating that Labcorp is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardinal Health 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Labcorp 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Labcorp (LH) Competitors

$265.80 +0.65 (+0.24%)

Closing price 06/5/2026 03:59 PM Eastern

Extended Trading

$264.85 -0.95 (-0.36%)

As of 09:17 AM Eastern

Compare

LH vs. HSIC, MEDP, AMN, BIO, and CAH

Should you buy Labcorp stock or one of its competitors? MarketBeat compares Labcorp with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Labcorp include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Bio-Rad Laboratories (BIO), and Cardinal Health (CAH). These companies are all part of the "medical" sector.

How does Labcorp compare to Henry Schein?

Labcorp (NYSE:LH) and Henry Schein (NASDAQ:HSIC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Labcorp has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Labcorp has a net margin of 6.66% compared to Henry Schein's net margin of 2.95%. Labcorp's return on equity of 16.29% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.66%	16.29%	7.62%
Henry Schein	2.95%	15.44%	5.53%

In the previous week, Henry Schein had 1 more articles in the media than Labcorp. MarketBeat recorded 10 mentions for Henry Schein and 9 mentions for Labcorp. Henry Schein's average media sentiment score of 1.61 beat Labcorp's score of 1.29 indicating that Henry Schein is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Henry Schein	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Labcorp has higher revenue and earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$14.14B	1.54	$876.50M	$11.29	23.54
Henry Schein	$13.38B	0.66	$398M	$3.31	23.40

95.9% of Labcorp shares are held by institutional investors. Comparatively, 96.6% of Henry Schein shares are held by institutional investors. 0.8% of Labcorp shares are held by insiders. Comparatively, 0.9% of Henry Schein shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Labcorp presently has a consensus target price of $308.00, indicating a potential upside of 15.88%. Henry Schein has a consensus target price of $86.83, indicating a potential upside of 12.12%. Given Labcorp's stronger consensus rating and higher possible upside, equities analysts clearly believe Labcorp is more favorable than Henry Schein.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Henry Schein	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

Summary

Labcorp beats Henry Schein on 12 of the 16 factors compared between the two stocks.

How does Labcorp compare to Medpace?

Labcorp (NYSE:LH) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Labcorp presently has a consensus price target of $308.00, indicating a potential upside of 15.88%. Medpace has a consensus price target of $467.08, indicating a potential upside of 2.83%. Given Labcorp's stronger consensus rating and higher possible upside, analysts plainly believe Labcorp is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.8% of Labcorp shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Labcorp has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Medpace has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Medpace has a net margin of 17.19% compared to Labcorp's net margin of 6.66%. Medpace's return on equity of 120.89% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.66%	16.29%	7.62%
Medpace	17.19%	120.89%	24.79%

In the previous week, Medpace had 36 more articles in the media than Labcorp. MarketBeat recorded 45 mentions for Medpace and 9 mentions for Labcorp. Labcorp's average media sentiment score of 1.29 beat Medpace's score of 0.27 indicating that Labcorp is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	13 Very Positive mention(s)	0 Positive mention(s)	30 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Labcorp has higher revenue and earnings than Medpace. Labcorp is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$14.14B	1.54	$876.50M	$11.29	23.54
Medpace	$2.68B	4.84	$451.12M	$15.91	28.55

Summary

Medpace beats Labcorp on 9 of the 16 factors compared between the two stocks.

How does Labcorp compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Labcorp (NYSE:LH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Labcorp has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.45	-$95.70M	-$0.87	N/A
Labcorp	$14.14B	1.54	$876.50M	$11.29	23.54

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 0.8% of Labcorp shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AMN Healthcare Services has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

In the previous week, AMN Healthcare Services had 2 more articles in the media than Labcorp. MarketBeat recorded 11 mentions for AMN Healthcare Services and 9 mentions for Labcorp. Labcorp's average media sentiment score of 1.29 beat AMN Healthcare Services' score of 0.31 indicating that Labcorp is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Labcorp	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services currently has a consensus target price of $25.29, suggesting a potential downside of 20.46%. Labcorp has a consensus target price of $308.00, suggesting a potential upside of 15.88%. Given Labcorp's stronger consensus rating and higher possible upside, analysts clearly believe Labcorp is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Labcorp has a net margin of 6.66% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Labcorp	6.66%	16.29%	7.62%

Summary

Labcorp beats AMN Healthcare Services on 12 of the 16 factors compared between the two stocks.

How does Labcorp compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Labcorp (NYSE:LH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Bio-Rad Laboratories currently has a consensus price target of $303.33, indicating a potential upside of 3.17%. Labcorp has a consensus price target of $308.00, indicating a potential upside of 15.88%. Given Labcorp's stronger consensus rating and higher probable upside, analysts clearly believe Labcorp is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Bio-Rad Laboratories has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Labcorp has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

In the previous week, Labcorp had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 9 mentions for Labcorp and 3 mentions for Bio-Rad Laboratories. Labcorp's average media sentiment score of 1.29 beat Bio-Rad Laboratories' score of 0.43 indicating that Labcorp is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Labcorp	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Labcorp has a net margin of 6.66% compared to Bio-Rad Laboratories' net margin of 6.52%. Labcorp's return on equity of 16.29% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
Labcorp	6.66%	16.29%	7.62%

Labcorp has higher revenue and earnings than Bio-Rad Laboratories. Labcorp is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.05	$759.90M	$6.07	48.44
Labcorp	$14.14B	1.54	$876.50M	$11.29	23.54

65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 0.8% of Labcorp shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Labcorp beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Labcorp compare to Cardinal Health?

Cardinal Health (NYSE:CAH) and Labcorp (NYSE:LH) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, Labcorp had 5 more articles in the media than Cardinal Health. MarketBeat recorded 9 mentions for Labcorp and 4 mentions for Cardinal Health. Labcorp's average media sentiment score of 1.29 beat Cardinal Health's score of 0.80 indicating that Labcorp is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardinal Health	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Labcorp	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Labcorp has a net margin of 6.66% compared to Cardinal Health's net margin of 0.62%. Labcorp's return on equity of 16.29% beat Cardinal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardinal Health	0.62%	-92.61%	4.46%
Labcorp	6.66%	16.29%	7.62%

Cardinal Health pays an annual dividend of $2.04 per share and has a dividend yield of 1.0%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 1.1%. Cardinal Health pays out 31.2% of its earnings in the form of a dividend. Labcorp pays out 25.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has increased its dividend for 29 consecutive years. Labcorp is clearly the better dividend stock, given its higher yield and lower payout ratio.

Cardinal Health presently has a consensus target price of $241.80, indicating a potential upside of 17.50%. Labcorp has a consensus target price of $308.00, indicating a potential upside of 15.88%. Given Cardinal Health's stronger consensus rating and higher possible upside, research analysts clearly believe Cardinal Health is more favorable than Labcorp.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardinal Health	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Cardinal Health has higher revenue and earnings than Labcorp. Labcorp is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardinal Health	$222.58B	0.22	$1.56B	$6.54	31.47
Labcorp	$14.14B	1.54	$876.50M	$11.29	23.54

Cardinal Health has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

87.2% of Cardinal Health shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 0.1% of Cardinal Health shares are held by company insiders. Comparatively, 0.8% of Labcorp shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Labcorp beats Cardinal Health on 12 of the 20 factors compared between the two stocks.

Get Labcorp News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LH vs. The Competition

Export

Metric	Labcorp	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$21.80B	$8.71B	$6.46B	$23.04B
Dividend Yield	1.10%	1.76%	2.67%	4.08%
P/E Ratio	23.54	22.75	23.90	30.25
Price / Sales	1.54	20.29	483.49	78.20
Price / Cash	10.68	12.81	26.99	18.46
Price / Book	2.56	5.20	10.34	4.62
Net Income	$876.50M	$177.20M	$3.57B	$1.07B
7 Day Performance	3.47%	-1.56%	-0.93%	-1.82%
1 Month Performance	4.65%	6.38%	3.54%	-1.22%
1 Year Performance	4.68%	3.44%	23.79%	21.20%

Labcorp Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LH Labcorp	4.24 of 5 stars	$265.80 +0.2%	$308.00 +15.9%	+4.7%	$21.80B	$14.14B	23.54	71,000	Positive News
HSIC Henry Schein	3.9739 of 5 stars	$76.40 -0.2%	$86.83 +13.7%	+10.1%	$8.72B	$13.38B	23.08	25,000	Positive News
MEDP Medpace	2.2194 of 5 stars	$451.47 +1.0%	$467.08 +3.5%	+53.2%	$12.77B	$2.68B	28.38	6,200
AMN AMN Healthcare Services	1.6731 of 5 stars	$29.47 +1.7%	$25.29 -14.2%	+50.7%	$1.12B	$2.73B	N/A	2,664	Analyst Revision Gap Down
BIO Bio-Rad Laboratories	1.2984 of 5 stars	$305.46 -2.2%	$303.33 -0.7%	+33.4%	$8.36B	$2.58B	50.32	7,450

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:LH) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Labcorp (LH) Competitors

LH vs. HSIC, MEDP, AMN, BIO, and CAH

How does Labcorp compare to Henry Schein?

Summary

How does Labcorp compare to Medpace?

Summary

How does Labcorp compare to AMN Healthcare Services?

Summary

How does Labcorp compare to Bio-Rad Laboratories?

Summary

How does Labcorp compare to Cardinal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LH vs. The Competition

Labcorp Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Labcorp (LH) Competitors

LH vs. HSIC, MEDP, AMN, BIO, and CAH

How does Labcorp compare to Henry Schein?

Which has more risk and volatility, LH or HSIC?

Is LH or HSIC more profitable?

Does the media favor LH or HSIC?

Which has higher valuation and earnings, LH or HSIC?

Do institutionals and insiders believe in LH or HSIC?

Do analysts prefer LH or HSIC?

Summary

How does Labcorp compare to Medpace?

Do analysts prefer LH or MEDP?

Do institutionals & insiders believe in LH or MEDP?

Which has more risk & volatility, LH or MEDP?

Is LH or MEDP more profitable?

Does the media prefer LH or MEDP?

Which has better earnings & valuation, LH or MEDP?

Summary

How does Labcorp compare to AMN Healthcare Services?

Which has preferable valuation and earnings, AMN or LH?

Do institutionals & insiders hold more shares of AMN or LH?

Which has more risk & volatility, AMN or LH?

Does the media refer more to AMN or LH?

Do analysts prefer AMN or LH?

Is AMN or LH more profitable?

Summary

How does Labcorp compare to Bio-Rad Laboratories?

Do analysts recommend BIO or LH?

Which has more risk & volatility, BIO or LH?

Does the media favor BIO or LH?

Is BIO or LH more profitable?

Which has stronger earnings & valuation, BIO or LH?

Do insiders and institutionals believe in BIO or LH?

Summary

How does Labcorp compare to Cardinal Health?

Does the media prefer CAH or LH?

Is CAH or LH more profitable?

Is CAH or LH a better dividend stock?

Do analysts recommend CAH or LH?

Which has better valuation and earnings, CAH or LH?

Which has more risk & volatility, CAH or LH?

Do insiders and institutionals hold more shares of CAH or LH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LH vs. The Competition

Labcorp Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools